Search Results
May 12, 2026, 23:33 ET WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
long-term economic, environmental and social performance, selecting from the largest 2,500 global companies in the S&P Global Broad Market Index (BMI) and from the largest 800 companies across 20 emerging markets, respectively.Based on the 2025 CSA, WuXi Biologics ranked among the top 1% globally
More news about: WuXi Biologics
May 12, 2026, 07:05 ET Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
cohort = 30 mg x 2 weeks, 60 mg x 2 weeks, 90 mg x 2 weeks, 120 mg x 7 weeks. 3) All enrolled participants were required to have baseline BMI ≥30 kg/m2 or BMI≥27 kg/m2 with at least one weight-related comorbid condition. 4) Least squares mean. 5) Two-sided t-test using mixed model for
More news about: Viking Therapeutics, Inc.
May 11, 2026, 14:12 ET Weight Management Market to Reach USD 381.5 Billion, Globally, by 2033 at 10.3% CAGR: Allied Market Research
period. In the United States specifically, this dominance is driven by an obesity epidemic at critical levels over 40% of adults are categorized by BMI as having obesity according to CDC data. The area is staffed with robust healthcare infrastructure, high penetration for covering obesity-related injunctive
More news about: Allied Market Research
May 08, 2026, 10:15 ET BMI ALERT: Investigation Launched into Badger Meter, Inc., Investors are Encouraged to Contact KTMC Law Firm
NYSE: BMI) on behalf of investors who purchased or acquired BMI securities and experienced significant financial losses.
More news about: Kessler Topaz Meltzer & Check, LLP
May 07, 2026, 13:00 ET Las Vegas Sands Continues on the Dow Jones Best-in-Class Indices for World and North America
through the Corporate Sustainability Assessment (CSA). It represents the top 10% of the largest 2,500 companies in the S&P Global Broad Market Index (BMI) based on long-term economic, environmental and social criteria. The Dow Jones Best-in-Class North America and Asia Pacific indices represent the top
More news about: Las Vegas Sands Corp.
May 07, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Badger Meter, Inc. - BMI
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
May 06, 2026, 06:00 ET The Ultimate Health Power Couple: Receive a Complimentary Withings Body Smart Scale ($129.95 MSRP) with Select Galaxy Watch Purchase
between both platforms. Samsung users can view their step data in the Withings app, while Withings users can see their weight, body fat percentage, and BMI in Samsung Health. Users can enable this integration through the Health Connect feature within each app's settings.What Withings and Samsung
More news about: Withings
May 05, 2026, 10:00 ET AI Model Analyses Body Composition to Predict Health Risks
Clinicians have long relied on body mass index (BMI) and body weight to estimate cardiometabolic—the connection between cardiovascular (heart/blood vessel) and metabolic (energy/nutrient processing) systems on health—and overall health risk. But BMI is a crude measure of body composition that only
More news about: Radiological Society of North America (RSNA)
May 05, 2026, 10:00 ET AI Model Analyses Body Composition to Predict Health Risks
Clinicians have long relied on body mass index (BMI) and body weight to estimate cardiometabolic—the connection between cardiovascular (heart/blood vessel) and metabolic (energy/nutrient processing) systems on health—and overall health risk. But BMI is a crude measure of body composition that only
More news about: Radiological Society of North America (RSNA)
May 05, 2026, 09:00 ET New Mayo Clinic Studies Demonstrate MyPhenome Test Predicts Weight Loss Outcomes Across Treatments, Including GLP-1s and Surgical Interventions
treated with a one-size-fits-all approach, and that identifying the right patient for the right therapy requires deeper biological characterization than BMI or weight history alone."Every patient who struggles with obesity deserves to know why and what will actually work for them," said Andres Acosta,
More news about: Phenomix Sciences
May 05, 2026, 08:20 ET BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint and All Key Secondary Endpoints
remained largely free of antihypertensive medications during the study. Enrolled participants had a mean baseline body weight of 96.2 kg and mean baseline BMI of 33.9 kg/m². Baseline characteristics were well-balanced across treatment groups. Participants were randomized to receive BGM0504 injection at doses
More news about: BrightGene
May 01, 2026, 16:05 ET Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
participants with obesity at baseline (body mass index [BMI] ≥85th percentile), 60% achieved clinically meaningful improvements (≥0.2 reduction) in BMI standard deviation score (SDS) at Month 24 with CRENESSITY, including 23% who achieved a BMI <85th percentile.Among participants with insulin
More news about: Neurocrine Biosciences, Inc.
May 01, 2026, 13:17 ET BMI Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Badger Meter, Inc. (NYSE: BMI) Investors to Contact the Firm
NYSE: BMI) on behalf of investors who purchased or acquired BMI securities and experienced significant financial losses.
More news about: Kessler Topaz Meltzer & Check, LLP
May 01, 2026, 06:59 ET Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting
The investigational treatment is a once-weekly transdermal contraceptive patch being developed for women of childbearing potential with a BMI below 30 kg/m² who are appropriate candidates for combined hormonal contraception (CHC) and who prefer a non-invasive, reversible option with a lower
More news about: Viatris Inc.
Apr 30, 2026, 21:42 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Badger Meter, Inc. - BMI
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Badger Meter, Inc. ("Badger Meter" or the "Company") (NYSE: BMI). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Apr 29, 2026, 16:05 ET Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
various VK2735 maintenance dosing regimens. This trial is a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2). All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for an induction period, after which participants are
More news about: Viking Therapeutics, Inc.
Apr 29, 2026, 12:00 ET BMI Imaging Attends IIMDA Spring 2026 Leadership Forum in Ponte Vedra
https://iimda.org/.About BMI Imaging SystemsFounded in 1958, BMI Imaging Systems helps organizations convert paper, microfilm, and microfiche into secure, searchable digital collections. BMI provides public, private, and CJIS-compliant hosting solutions
More news about: BMI Imaging Systems, Inc.
Apr 29, 2026, 07:47 ET AbbVie Reports First-Quarter 2026 Financial Results
of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. In the study, ABBV-295 treatment showed clinically meaningful body weight reduction at week 12 (weekly dosing) and
More news about: AbbVie
Apr 24, 2026, 16:25 ET Cerapedics Announces Supplier Agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft
the first and only bone growth accelerator demonstrated to increase lumbar fusion in both overall and higher-risk patient populations (nicotine use, BMI≥30 and/or type 2 diabetes). The results are based on data from the pivotal ASPIRE TLIF Investigational Device Exemption (IDE) study, now published in
More news about: Cerapedics Inc.
Apr 24, 2026, 09:08 ET MEMORIAL ADVANCES KIDNEY TRANSPLANT CARE WITH ROBOTIC SURGERY FOR DONORS AND RECIPIENTS
reducing the physical impact of surgery, robotic-assisted kidney transplant surgery may also expand access for some patients with higher body mass index (BMI), who can face increased risk of wound complications with traditional open surgery."We are proud of our multidisciplinary team for continuing
More news about: Memorial Healthcare System
Apr 22, 2026, 11:14 ET Mô hình chăm sóc kết hợp của NOVI Health thu hẹp khoảng cách giữa thử nghiệm lâm sàng và kết quả thực tế khi sử dụng GLP-1
điểm phần trăm so với những người ít tương tác, tương đương mức giảm cân tương đối cao hơn khoảng 15%Giảm BMI nhiều hơn ~0,72 kg/m²Giảm thêm tới 2,9 mmHg huyết áp tâm thuKhông
More news about: NOVI Health
Apr 22, 2026, 11:13 ET Model Perawatan Terpadu NOVI Health Hapus Kesenjangan antara Hasil Uji Klinis dan Penerapan Obat GLP-1 di Dunia Nyata
persentase dibandingkan peserta program yang kurang aktif—setara dengan peningkatan relatif sekitar 15%Penurunan indeks massa tubuh (BMI) juga lebih besar, yakni sekitar 0,72 kg/m²Tambahan penurunan tekanan darah sistolik hingga 2,9 mmHg.Hasil Setiap
More news about: NOVI Health
Apr 18, 2026, 04:50 ET Saint Anthony Hospital Provides Diet Advice for Healthy Kids Day
excess weight: Speak with the child's pediatrician, who can review growth charts and BMI percentiles and evaluate related health concernsFocus on family lifestyle changes rather than single out the childMake small, sustainable
More news about: Saint Anthony Hospital
Apr 16, 2026, 06:45 ET ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
open-label trial evaluating the efficacy and safety of Foundayo compared with insulin glargine in adults with type 2 diabetes and obesity or overweight (BMI ≥25 kg/m2) with increased risk of cardiovascular events. The trial randomized 2,749 participants across the U.S., Argentina, Austria, Brazil,
More news about: Eli Lilly and Company
Apr 15, 2026, 08:00 ET PrecisionLife and Ovation ink collaboration agreement to launch GLP-1 stratification LDT and consumer GLP-1 DNA test in H2 2026
confirmed that they have identified novel quantitative markers for strong glycemic control (HbA1c) that are specific and different to those for weight loss (BMI) in a real-world population. PrecisionLife will reproduce, refine, and validate these findings in additional datasets provided by Ovation.io, including
More news about: PrecisionLife Ltd